V Brodszky

Summary

Affiliation: Corvinus University of Budapest
Country: Hungary

Publications

  1. ncbi request reprint Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
    Valentin Brodszky
    Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary
    Eur J Health Econ 15:65-71. 2014
  2. doi request reprint [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Egészség gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont, Budapest, Fővám tér 8 1093
    Orv Hetil 154:890-9. 2013
  3. ncbi request reprint [Rituximab in patients with rheumatoid arthritis: systematic review]
    Valentin Brodszky
    Budapesti Corvinus Egyetem, Közszolgálati Tanszék, Egészségügyi Gazdaságtani és Technológiaelemzési Kutatóközpont, Budapest
    Orv Hetil 148:1883-93. 2007
  4. doi request reprint Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey
    V Brodszky
    Health Economics and Technology Assessment Research Centre, Corvinus University of Budapest, Budapest, Fővám tér 8, Hungary
    Scand J Rheumatol 39:303-9. 2010
  5. ncbi request reprint [The efficacy of indapamide in different cardiovascular outcome--meta-analysis]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Közszolgálati Tanszék, Egészségügyi Gazdaságtani és Technológiaelemzési Kutatóközpont, Budapest
    Orv Hetil 148:1203-11. 2007
  6. doi request reprint [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Egészség gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont Budapest Fővám tér 8 1093
    Orv Hetil 152:919-28. 2011
  7. doi request reprint Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment
    Valentin Brodszky
    Health Economics and Technology Assessment Research Centre, Corvinus University of Budapest, Fővám tér 8, 1093 Budapest, Hungary
    Rheumatol Int 30:199-205. 2009
  8. doi request reprint [Effectiveness of prostanoids in patients with critical leg ischemia]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Egészség gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont Budapest Fővám tér 8 1093
    Orv Hetil 152:2047-55. 2011
  9. ncbi request reprint Costs of dementia in Hungary
    K Ersek
    Corvinus University of Budapest, Health Economics and Health Technology Assessment Research Centre, Budapest, Hungary
    J Nutr Health Aging 14:633-9. 2010
  10. ncbi request reprint Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999-2003
    M Pentek
    Rheumatology, Flór Ferenc County Hospital, Semmelweis tér 1, Kistarcsa 2143, Hungary
    Osteoporos Int 19:243-9. 2008

Detail Information

Publications21

  1. ncbi request reprint Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
    Valentin Brodszky
    Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary
    Eur J Health Econ 15:65-71. 2014
    ..Further savings are expected for other indications where biosimilar medicines are implemented. ..
  2. doi request reprint [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Egészség gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont, Budapest, Fővám tér 8 1093
    Orv Hetil 154:890-9. 2013
    ..Limited number of new pharmaceutical products have been developed and registered in the past decades for the treatment of Clostridium difficile infection. The available scientific evidence is limited and hardly comparable...
  3. ncbi request reprint [Rituximab in patients with rheumatoid arthritis: systematic review]
    Valentin Brodszky
    Budapesti Corvinus Egyetem, Közszolgálati Tanszék, Egészségügyi Gazdaságtani és Technológiaelemzési Kutatóközpont, Budapest
    Orv Hetil 148:1883-93. 2007
    ..Rituximab was registered to be used in patients with rheumatoid arthritis who have had an inadequate response or an intolerance to one or more TNF-alpha blocking agents...
  4. doi request reprint Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey
    V Brodszky
    Health Economics and Technology Assessment Research Centre, Corvinus University of Budapest, Budapest, Fővám tér 8, Hungary
    Scand J Rheumatol 39:303-9. 2010
    ....
  5. ncbi request reprint [The efficacy of indapamide in different cardiovascular outcome--meta-analysis]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Közszolgálati Tanszék, Egészségügyi Gazdaságtani és Technológiaelemzési Kutatóközpont, Budapest
    Orv Hetil 148:1203-11. 2007
    ..This kind of efficacy of thiazides type diuretics were published earlier in several studies. The efficacy of indapamide was investigated in several studies, but there is no analysis which is including all of the indapamide-studies...
  6. doi request reprint [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Egészség gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont Budapest Fővám tér 8 1093
    Orv Hetil 152:919-28. 2011
    ..These trials were different in patient characteristics and the administration regimen. Placebo was the control and direct comparison of biological treatments is missing...
  7. doi request reprint Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment
    Valentin Brodszky
    Health Economics and Technology Assessment Research Centre, Corvinus University of Budapest, Fővám tér 8, 1093 Budapest, Hungary
    Rheumatol Int 30:199-205. 2009
    ..Our study revealed that functional status and severity of skin symptoms were the key cost drivers. The costs of PsA in Hungary were lower than in the high-income European countries...
  8. doi request reprint [Effectiveness of prostanoids in patients with critical leg ischemia]
    Valentin Brodszky
    Budapesti Corvinus Egyetem Egészség gazdaságtani és Egészségügyi Technológiaelemzési Kutatóközpont Budapest Fővám tér 8 1093
    Orv Hetil 152:2047-55. 2011
    ..According to a Cochrane analysis (CD006544) prostanoids differ in their effects on rest-pain relief and ulcer healing...
  9. ncbi request reprint Costs of dementia in Hungary
    K Ersek
    Corvinus University of Budapest, Health Economics and Health Technology Assessment Research Centre, Budapest, Hungary
    J Nutr Health Aging 14:633-9. 2010
    ..The main aim of this paper is to give an overview on the quality of life, health care utilisation and costs of dementia in Hungary...
  10. ncbi request reprint Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999-2003
    M Pentek
    Rheumatology, Flór Ferenc County Hospital, Semmelweis tér 1, Kistarcsa 2143, Hungary
    Osteoporos Int 19:243-9. 2008
    ..On average, there were 343 hip, 1,579 forearm, 342 proximal humerus, 48 inpatient vertebral and 2,459 other fractures/100,000 inhabitants/year...
  11. ncbi request reprint Challenges in economic evaluation of new drugs: experience with rituximab in Hungary
    Valentin Brodszky
    Health Economics and Technology Assessment Research Centre, Corvinus University of Budapest, Budapest, Hungary
    Med Sci Monit 16:SR1-5. 2010
    ..Various countries have different requirements for information but most often focus on economic evaluation, which often plays a stronger role in healthcare decision making than does clinical evidence...
  12. doi request reprint History of health technology assessment in Hungary
    Laszlo Gulacsi
    Department of Public Policy and Management, Corvinus University of Budapest, Hungary
    Int J Technol Assess Health Care 25:120-6. 2009
    ..This article describes the characteristic features of the Hungarian healthcare system, the history and the current role of HTA, and the most important challenges...
  13. doi request reprint [Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary]
    Marta Pentek
    Pest Megyei Flór Ferenc Kórház, Reumatológiai és Fizioterápiás Osztály, Kistarcsa
    Orv Hetil 149:733-41. 2008
    ..Rheumatoid arthritis (RA) is a chronic, progressive polyarthritis leading to substantial disability. Standardised data on consequences of disease progression are needed for clinical assessments and also for cost-effectiveness models...
  14. ncbi request reprint [Mortality of hospitalized stroke patients in Hungary; 2003-2005]
    Laszlo Gulacsi
    Budapesti Corvinus Egyetem, Közszolgálati Tanszék, Egészség gazdaságtani és Technológiaelemzési Kutatóközpont, HunHTA, Budapest
    Ideggyogy Sz 60:321-8. 2007
    ..70-fold in men in the total sample, and 10-15-fold in the 45-64 group. There are large differences by gender, particularly in men of the working age groups (25-44, 45-64), whose mortality is twice as high as that of women of the same age...
  15. ncbi request reprint [The effectiveness of carvedilol in heart failure]
    Krisztian Karpati
    Egészség gazdaságtani és Technológiaelemzési Munkacsoport, Közszolgálati Tanszék, Budapest
    Orv Hetil 147:1931-7. 2006
    ....
  16. ncbi request reprint [Health care costs of acute myocardial infarction in Hungary, 2003-2005]
    Laszlo Gulacsi
    Budapesti Corvinus Egyetem, Egészség gazdaságtani és Technológiaelemzési Kutatóközpont, Közszolgálati Tanszék, Fővám tér 8, 1093 Budapest
    Orv Hetil 148:1259-66. 2007
    ..The morbidity of acute myocardial infarction (AMI) is remarkable in Hungary, therefore understanding the disease burden more accurately is inevitable...
  17. doi request reprint Adherence to biologic DMARD therapies in rheumatoid arthritis
    Tamas Koncz
    Semmelweis University, Budapest, Hungary
    Expert Opin Biol Ther 10:1367-78. 2010
    ..The efficacy of the biologic disease-modifying antirheumatic drugs (DMARDs) shown in clinical trials may be jeopardized due to prevalent poor patient adherence...
  18. ncbi request reprint Costs of rheumatoid arthritis in Hungary
    Marta Pentek
    J Rheumatol 34:1437. 2007
  19. ncbi request reprint [The role of biological agents in the treatment of psoriatic arthritis, literature review]
    Éva Koó
    Budai Irgalmasrendi Kórház, II Reumatológiai Osztály
    Orv Hetil 147:1963-70. 2006
    ..TNF-alpha inhibitors available in Hungary (infliximab, etanercept, adalimumab) are potential therapies for patients who have not adequately responded to traditional disease-modifying antirheumatic drugs...
  20. ncbi request reprint [The role of biologic agents in the therapy of ankylosing spondylitis]
    Pál Géher
    Semmelweis Egyetem, Általános Orvostudományi Kar, Ill Belgyógyászati Klinika, Reumatológiai és Fizioterápiás Tanszéki Csoport, Budai Irgalmasrendi Kórház, I Reumatológiai Osztály, Budapest
    Orv Hetil 147:1203-13. 2006
    ..Though individual admission is feasible, biologic drugs are not under reimbursement in Hungary. High drug costs makes the implementation of this new therapeutic opportunity difficult in the daily medical practice...
  21. ncbi request reprint [The role of biological drugs in the treatment of psoriasis, results from 9 randomized placebo-controlled trials]
    Lajos Kemeny
    Szegedi Tudomanyegyetem, Szent Györgyi Albert Orvos és Gyógyszerésztudományi Centrum, Bőrgyógyászati és Allergológiai Klinika
    Orv Hetil 147:981-90. 2006
    ..In the years past more trials were published, which are examining the efficacy of different biological drugs. There is no analysis which is including all the trials with biological drugs...